Valuation: RetinalGenix Technologies Inc.

Market Cap 75.37M 65.12M 61.26M 55.66M 105M 7.19B 106M 717M 280M 3.61B 283M 277M 12B P/E 2024
-21.8x
P/E 2025 -24.5x
Enterprise Value 75.9M 65.58M 61.69M 56.05M 105M 7.24B 107M 722M 282M 3.63B 285M 279M 12.08B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
34.7%
Yield 2024 *
-
Yield 2025 -
08-14 RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-21 RetinalGenix Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-15 RetinalGenix Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
04-15 RetinalGenix Technologies Inc. Auditor Raises 'Going Concern' Doubt CI
03-26 Retinalgenix Technologies Inc. Announces Resignation of Michael Cory Zwerling as Chief Financial Officer, Effective March 22, 2026 CI
01-14 RetinalGenix Technologies Inc. Reports on Its Science and Mission in Light of New AI-Driven Retinal Mapping Study CI
12-09 RetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Chief Financial Officer, Effective January 1, 2026 CI
12-09 RetinalGenix Technologies Inc. Appoints M. Cory Zwerling as Interim Chief Operating Officer, Effective January 1, 2026 CI
11-15 RetinalGenix Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
01/10/25 RetinalGenix Technologies Inc. and RGEN Inc. Clinical Genotyping Laboratory Announce Strategic Collaboration to Advance Early Detection of Neurodegenerative, Systemic, and Retinal Diseases CI
01/10/25 RetinalGenix and RGEN Clinical Genotyping Lab partner to advance early disease detection RE
19/08/25 RetinalGenix Technologies Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
28/06/25 RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening CI
1 day-11.25%
1 week-11.25%
Current month-11.25%
1 month-11.25%
3 months-11.25%
6 months+10.94%
Current year+10.94%
Current year 3.55
Extreme 3.55
4
1 year 3.2
Extreme 3.2
4.01
3 years 0.25
Extreme 0.25
6.36
5 years 0.25
Extreme 0.25
20
10 years 0.25
Extreme 0.25
20
Manager TitleAgeSince
Chief Executive Officer 73 01/12/2018
Director TitleAgeSince
Chairman 73 01/12/2018
Director/Board Member 97 01/04/2019
Director/Board Member 58 26/07/2022
Change 5-day change 1-year change 3-year change Capi.($)
-11.25%-11.25%+0.28%-62.23% 75.37M
-1.78%-1.68%+1.48%+15.31% 48.42B
+0.85%-0.70%+460.88%+563.55% 43.66B
-2.40%-0.23%+8.13%+71.41% 39.51B
-2.01%-0.85%+23.85%+8.73% 38.95B
-0.50%+0.85%+20.60%+49.65% 32.61B
+0.38%-3.23% - - 16.32B
-0.59%-2.06%+26.35%+118.09% 16.15B
+0.49%+0.92%+4.11%+23.67% 14.16B
-0.43%+4.70%+78.74%+33.31% 13.37B
Average -1.72%+0.44%+69.38%+91.28% 26.32B
Weighted average by Cap. -0.92%+0.59%+95.80%+132.89%

Financials

2024 2025
Net sales - -
Net income -4.32M -3.73M -3.51M -3.19M -5.99M -412M -6.1M -41.12M -16.07M -207M -16.22M -15.87M -688M -2.43M -2.1M -1.97M -1.79M -3.37M -232M -3.43M -23.11M -9.03M -116M -9.11M -8.92M -387M
Net Debt 518K 448K 421K 383K 719K 49.45M 731K 4.93M 1.93M 24.8M 1.95M 1.9M 82.48M 530K 458K 431K 391K 735K 50.57M 748K 5.04M 1.97M 25.36M 1.99M 1.95M 84.35M
Logo RetinalGenix Technologies Inc.
RetinalGenix Technologies Inc. is an ophthalmic research and development company seeking to revolutionize early disease detection and improve patient outcomes across multiple disease areas. The Company's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. It is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.
Employees
-
  1. Stock Market
  2. Stocks
  3. RTGN Stock